Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

The Two-State Receptor Model

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Toxicity, Chemistry, and Public Health Relevance of Emerging Nicotine Analog Vapes, Pods, and Pouches.

Chemical research in toxicology·2026

Same author

Obesity-related differences in amygdala and hippocampal volume and metabolism before and after a placebo-controlled antidepressant trial in major depressive disorder.

Scientific reports·2026

Same author

Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Toxicity and health effects of delta-8, delta-9, and delta-10-tetrahydrocannabinol and unregulated cannabinoids in vaping products.

Toxicology reports·2026

Same author

Toxicity of humectants propylene glycol and vegetable glycerin in electronic nicotine delivery systems.

Toxicology letters·2025

Same author

iACT4IBD: a randomised controlled trial of a brief online intervention based on acceptance and commitment therapy to improve wellbeing for adults with inflammatory bowel disease.

Frontiers in digital health·2025

Search research articles

Related Experiment Video

Updated: Jun 26, 2026

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

Characterizing cannabinoid CB2 receptor ligands using DiscoveRx PathHunter beta-arrestin assay.

Debra McGuinness¹, Asra Malikzay, Richard Visconti

¹New Lead Discovery, Schering-Plough Research Institute, Kenilworth, New Jersey, USA.

Journal of Biomolecular Screening

|January 28, 2009

Summary

This study validates a new cell-based assay for screening cannabinoid CB(2) receptor ligands. The beta-arrestin interaction assay offers a robust and reliable platform for identifying specific CB(2) compounds.

More Related Videos

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay

Published on: March 10, 2020

BRET-based G Protein Biosensors for Measuring G Protein-Coupled Receptor Activity in Live Cells

BRET-based G Protein Biosensors for Measuring G Protein-Coupled Receptor Activity in Live Cells

Published on: November 7, 2025

Related Experiment Videos

Last Updated: Jun 26, 2026

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay

Published on: March 10, 2020

BRET-based G Protein Biosensors for Measuring G Protein-Coupled Receptor Activity in Live Cells

BRET-based G Protein Biosensors for Measuring G Protein-Coupled Receptor Activity in Live Cells

Published on: November 7, 2025

Area of Science:

Pharmacology
Biochemistry
Assay Development

Background:

Cannabinoid CB(2) receptor ligands are crucial for therapeutic development.
Existing assay methods for screening these ligands have limitations.
A robust and validated screening platform is needed for efficient drug discovery.

Purpose of the Study:

To characterize cannabinoid CB(2) receptor ligands using a cell-based beta-arrestin interaction assay.
To compare the performance of this assay with traditional ligand binding and cAMP assays.
To validate the beta-arrestin assay as a reliable screening platform.

Main Methods:

Utilized the DiscoveRx PathHunter assay for receptor/beta-arrestin interaction.
Compared results with competitive ligand binding assays and forskolin-stimulated cAMP assays (PerkinElmer LANCE).
Validated the assay using cryopreserved cell suspensions for improved consistency.

Main Results:

Demonstrated good correlation across the three tested assay systems.
The beta-arrestin assay showed a more robust signal than the cAMP assay for CB(2) agonists.
The assay is suitable for screening from cryopreserved cells, reducing variability.

Conclusions:

The ligand-induced interaction between the human cannabinoid CB(2) receptor and beta-arrestin is a valuable screening platform.
The DiscoveRx PathHunter HEK293 CB(2) beta-arrestin assay is validated for specific compound screening.
This assay offers an improved method for identifying cannabinoid CB(2) receptor ligands.